These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1770066)

  • 1. Effect of urokinase on preservation of renal function in patients with diabetic nephropathy.
    Sakai H; Watanabe S; Inoue I; Tanaka K; Yagame M; Machimura H; Kaneshige H; Nomoto Y
    J Diabet Complications; 1991; 5(2-3):95-7. PubMed ID: 1770066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silent cerebral infarction in patients with type 2 diabetic nephropathy. Effects of antiplatelet drug dilazep dihydrochloride.
    Nakamura T; Kawagoe Y; Matsuda T; Ueda Y; Ebihara I; Koide H
    Diabetes Metab Res Rev; 2005; 21(1):39-43. PubMed ID: 15386824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Administration of aspirin-dipyridamole reduces proteinuria in diabetic nephropathy.
    Hopper AH; Tindall H; Davies JA
    Nephrol Dial Transplant; 1989; 4(2):140-3. PubMed ID: 2496357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the antiplatelet agents, dipyridamole and dilazep dihydrochloride, on in vivo platelet function and proteinuria.
    Inage H; Koyama A; Narita M; Tojo S
    Nihon Jinzo Gakkai Shi; 1985 Sep; 27(9):1261-70. PubMed ID: 4087547
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of the antiplatelet drug dilazep dihydrochloride on urinary podocytes in patients in the early stage of diabetic nephropathy.
    Nakamura T; Ushiyama C; Shimada N; Sekizuka K; Ebihara I; Hara M; Koide H
    Diabetes Care; 2000 Aug; 23(8):1168-71. PubMed ID: 10937516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy.
    Khajehdehi P; Roozbeh J; Mostafavi H
    Scand J Urol Nephrol; 2002; 36(2):145-8. PubMed ID: 12028688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dilazep hydrochloride, an antiplatelet drug, prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats.
    Yamagishi S; Koga K; Inagaki Y; Amano S; Okamoto T; Takeuchi M
    Drugs Exp Clin Res; 2002; 28(6):221-7. PubMed ID: 12776575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical effect of the anti-platelet drug, dilazep dihydrochloride, in patients at the microalbuminuric stage of diabetic nephropathy--a multi-center study.
    Koide H; Totsuka Y; Sugisaki T; Kitajima T; Ohmori Y; Kuriyama S; Oi K; Isogai S; Ohi H; Tomino Y
    Nihon Jinzo Gakkai Shi; 1995 Nov; 37(11):644-8. PubMed ID: 8583701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of pancreatic elastase on diabetic nephropathy.
    Nagai T; Tomizawa T; Mori M
    Diabetes Care; 1993 Aug; 16(8):1214-5. PubMed ID: 8375257
    [No Abstract]   [Full Text] [Related]  

  • 10. Ameliorating effects of conventional therapy on declining renal function in patients with diabetic nephropathy.
    Machimura H
    Tokai J Exp Clin Med; 1991 Oct; 16(3-4):187-92. PubMed ID: 1811352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of microscopic haematuria in diabetic nephropathy in type 2 diabetes patients with overt proteinuria.
    Okada T; Nagao T; Matsumoto H; Nagaoka Y; Wada T; Nakao T
    Nephrology (Carlton); 2013 Aug; 18(8):563-8. PubMed ID: 23714217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of dilazep on urinary protein excretion in spontaneous diabetic Chinese hamster.
    Morikawa A; Eto M; Makino I
    Nephron; 1993; 65(1):125-32. PubMed ID: 8413770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of dipyridamole on proteinuria of diabetic nephropathy.
    Makino H; Okada S; Ota Z
    Clin Nephrol; 1983 Sep; 20(3):160. PubMed ID: 6627765
    [No Abstract]   [Full Text] [Related]  

  • 14. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
    de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
    Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of thiazolidinedione treatment on proteinuria and renal hemodynamic in type 2 diabetic patients with overt nephropathy.
    Pistrosch F; Passauer J; Herbrig K; Schwanebeck U; Gross P; Bornstein SR
    Horm Metab Res; 2012 Nov; 44(12):914-8. PubMed ID: 22723267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ; Lewis JB
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical indicators which necessitate renal biopsy in type 2 diabetes mellitus patients with renal disease.
    Lin YL; Peng SJ; Ferng SH; Tzen CY; Yang CS
    Int J Clin Pract; 2009 Aug; 63(8):1167-76. PubMed ID: 18422591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uncontrolled hypertension is associated with a rapid progression of nephropathy in type 2 diabetic patients with proteinuria and preserved renal function.
    Baba T; Murabayashi S; Tomiyama T; Takebe K
    Tohoku J Exp Med; 1990 Aug; 161(4):311-8. PubMed ID: 2256104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-β and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study.
    Khajehdehi P; Pakfetrat M; Javidnia K; Azad F; Malekmakan L; Nasab MH; Dehghanzadeh G
    Scand J Urol Nephrol; 2011 Nov; 45(5):365-70. PubMed ID: 21627399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of antiplatelet therapy for IgA nephropathy.
    Taji Y; Kuwahara T; Shikata S; Morimoto T
    Clin Exp Nephrol; 2006 Dec; 10(4):268-73. PubMed ID: 17186331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.